Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

282 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities.
Cheasley D, Nigam A, Zethoven M, Hunter S, Etemadmoghadam D, Semple T, Allan P, Carey MS, Fernandez ML, Dawson A, Köbel M, Huntsman DG, Le Page C, Mes-Masson AM, Provencher D, Hacker N, Gao Y, Bowtell D, deFazio A, Gorringe KL, Campbell IG. Cheasley D, et al. Among authors: hacker n. J Pathol. 2021 Jan;253(1):41-54. doi: 10.1002/path.5545. Epub 2020 Oct 28. J Pathol. 2021. PMID: 32901952
High levels of genomic aberrations in serous ovarian cancers are associated with better survival.
Baumbusch LO, Helland Å, Wang Y, Liestøl K, Schaner ME, Holm R, Etemadmoghadam D, Alsop K, Brown P; Australian Ovarian Cancer Study Group; Mitchell G, Fereday S, DeFazio A, Bowtell DD, Kristensen GB, Lingjærde OC, Børresen-Dale AL. Baumbusch LO, et al. PLoS One. 2013;8(1):e54356. doi: 10.1371/journal.pone.0054356. Epub 2013 Jan 23. PLoS One. 2013. PMID: 23372714 Free PMC article.
Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers.
Helland Å, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk N, Rustgi AK, Phillips WA, Johnsen H, Holm R, Kristensen GB, Birrer MJ; Australian Ovarian Cancer Study Group; Pearson RB, Børresen-Dale AL, Huntsman DG, deFazio A, Creighton CJ, Smyth GK, Bowtell DD. Helland Å, et al. PLoS One. 2011 Apr 13;6(4):e18064. doi: 10.1371/journal.pone.0018064. PLoS One. 2011. PMID: 21533284 Free PMC article.
ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.
Hedditch EL, Gao B, Russell AJ, Lu Y, Emmanuel C, Beesley J, Johnatty SE, Chen X, Harnett P, George J; Australian Ovarian Cancer Study Group; Williams RT, Flemming C, Lambrechts D, Despierre E, Lambrechts S, Vergote I, Karlan B, Lester J, Orsulic S, Walsh C, Fasching P, Beckmann MW, Ekici AB, Hein A, Matsuo K, Hosono S, Nakanishi T, Yatabe Y, Pejovic T, Bean Y, Heitz F, Harter P, du Bois A, Schwaab I, Hogdall E, Kjaer SK, Jensen A, Hogdall C, Lundvall L, Engelholm SA, Brown B, Flanagan J, Metcalf MD, Siddiqui N, Sellers T, Fridley B, Cunningham J, Schildkraut J, Iversen E, Weber RP, Berchuck A, Goode E, Bowtell DD, Chenevix-Trench G, deFazio A, Norris MD, MacGregor S, Haber M, Henderson MJ. Hedditch EL, et al. J Natl Cancer Inst. 2014 Jun 23;106(7):dju149. doi: 10.1093/jnci/dju149. Print 2014 Jul. J Natl Cancer Inst. 2014. PMID: 24957074 Free PMC article.
The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro.
O'Brien PM, Davies MJ, Scurry JP, Smith AN, Barton CA, Henderson MJ, Saunders DN, Gloss BS, Patterson KI, Clancy JL, Heinzelmann-Schwarz VA, Murali R, Scolyer RA, Zeng Y, Williams ED, Scurr L, Defazio A, Quinn DI, Watts CK, Hacker NF, Henshall SM, Sutherland RL. O'Brien PM, et al. Among authors: hacker nf. Br J Cancer. 2008 Mar 25;98(6):1085-93. doi: 10.1038/sj.bjc.6604281. Epub 2008 Mar 18. Br J Cancer. 2008. PMID: 18349819 Free PMC article.
Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium.
Olsen CM, Nagle CM, Whiteman DC, Ness R, Pearce CL, Pike MC, Rossing MA, Terry KL, Wu AH; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group; Risch HA, Yu H, Doherty JA, Chang-Claude J, Hein R, Nickels S, Wang-Gohrke S, Goodman MT, Carney ME, Matsuno RK, Lurie G, Moysich K, Kjaer SK, Jensen A, Hogdall E, Goode EL, Fridley BL, Vierkant RA, Larson MC, Schildkraut J, Hoyo C, Moorman P, Weber RP, Cramer DW, Vitonis AF, Bandera EV, Olson SH, Rodriguez-Rodriguez L, King M, Brinton LA, Yang H, Garcia-Closas M, Lissowska J, Anton-Culver H, Ziogas A, Gayther SA, Ramus SJ, Menon U, Gentry-Maharaj A, Webb PM; Ovarian Cancer Association Consortium. Olsen CM, et al. Endocr Relat Cancer. 2013 Mar 22;20(2):251-62. doi: 10.1530/ERC-12-0395. Print 2013 Apr. Endocr Relat Cancer. 2013. PMID: 23404857 Free PMC article.
Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls.
Terry KL, Karageorgi S, Shvetsov YB, Merritt MA, Lurie G, Thompson PJ, Carney ME, Weber RP, Akushevich L, Lo-Ciganic WH, Cushing-Haugen K, Sieh W, Moysich K, Doherty JA, Nagle CM, Berchuck A, Pearce CL, Pike M, Ness RB, Webb PM; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group; Rossing MA, Schildkraut J, Risch H, Goodman MT; Ovarian Cancer Association Consortium. Terry KL, et al. Cancer Prev Res (Phila). 2013 Aug;6(8):811-21. doi: 10.1158/1940-6207.CAPR-13-0037. Epub 2013 Jun 12. Cancer Prev Res (Phila). 2013. PMID: 23761272 Free PMC article.
Glycemic index, glycemic load and endometrial cancer risk: results from the Australian National Endometrial Cancer study and an updated systematic review and meta-analysis.
Nagle CM, Olsen CM, Ibiebele TI, Spurdle AB, Webb PM; Astralian National Endometrial Cancer Study Group; Astralian Ovarian Cancer Study Group. Nagle CM, et al. Eur J Nutr. 2013 Mar;52(2):705-15. doi: 10.1007/s00394-012-0376-7. Epub 2012 May 22. Eur J Nutr. 2013. PMID: 22648201 Review.
282 results